PITTSBURGH, March 15, 2000 -- Bayer Corporation, the largest producer of monodispersed resins in the world, introduces its new brochure: Bayer's WS Technologies - Fluidized Service. Downflow Regeneration. The brochure outlines Bayer's fluidized bed process in Ion Exchange Systems, describes its five different fluidized bed systems, and highlights its new line of Monoplus resins - all of which help deliver savings in water and regenerant costs.

The brochure also discusses how, since the early 1960s, Bayer has led the development effort behind modern packed bed countercurrent technology. Bayer's upflow exhaustion/ downflow regeneration concept led to the first patent in this field for WS or fluidized bed process. Three patents followed for the Liftbed, Rinsebed and Multipstep systems. With five systems from which to choose and a complete line of Lewatit® MonoPlus resins, Bayer systems can be customized to meet customers' plant requirements.

"Our customers are realizing the significant productivity and economic benefits of packed bed technology, particularly the advantages that downflow regeneration brings to the process," said Phil Fatula, Technical Manager, Ion Exchange Resins and Water Treatment Chemicals Group. "And, with five different WS systems to choose from and a complete line of Lewatit Monoplus resins, Bayer's complete offering provides effective solutions to meet the needs of any application."

For more information Bayer's ion exchange technology, contact: Bayer Corporation, Industrial Chemicals Communications, 100 Bayer Road, Pittsburgh, PA 15205; (800) 662-2927 ext. 5688; FAX (412) 777-3899. Or, visit Bayer's ion exchange Web sites at www.H20Treat.com, www.ion-exchange.com, www.phosphonate.com, and www.hydrazinehydrate.com. For information on Bayer Corporation, visit www.bayerus.com.

Bayer Corporation is a research-based company with major businesses in health care and life sciences and chemicals. The company had 1998 sales of $8.1 billion and employs more than 23,000 people. Bayer Corporation is investing $15 billion in capital expenditures and research and development from 1995 through the year 2004. 1999 capital investment and R&D expenditures are projected to total $1.6 billion. Bayer Corporation, with headquarters in Pittsburgh, is a member of the worldwide Bayer Group, a $31 billion international life sciences, polymers and specialty chemicals group based in Leverkusen, Germany.

Editor's Note - please send all reader service leads to the attention of Bryan Iams, Communications Representative, Bayer Corporation, 100 Bayer Road, Pittsburgh, Pa 15205.